Corporate GovernanceMay 27, 2026, 04:22 PM
Pacira Urges Stockholders to Vote FOR Board Nominees in Proxy Contest
AI Summary
Pacira BioSciences urged stockholders to vote for its board nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) at the upcoming Annual Meeting on June 9, 2026, amidst a proxy contest initiated by DOMA Perpetual Capital Management LLC. The company highlighted its "5x30 strategy" and strong 2025 financial performance, including record total revenues of $726.4 million and non-GAAP net income of $122.3 million. Pacira also emphasized the favorable EXPAREL settlement, which provides exclusivity into 2030, and its refreshed board's commitment to stockholder engagement.
Key Highlights
- Urges stockholders to vote "FOR" Pacira's nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.
- Reported 2025 record total revenues of $726.4 million.
- Achieved 2025 GAAP net income of $7.0 million ($0.16/share) and non-GAAP net income of $122.3 million ($2.65/diluted share).
- Delivered record GAAP Gross Margins of 79.4% and Non-GAAP Gross Margins of 81.2% in 2025.
- EXPAREL volume grew 6.2% in 2025, with 8% growth in the second half.
- Advanced two Phase 2 clinical programs: PCRX-201 for OA and PCRX-2002 for postsurgical pain.
- Expanded commercial reach via collaborations with Johnson & Johnson MedTech and LG Chem.
- Reached favorable EXPAREL settlement in 2025, ensuring exclusivity into 2030.
Price Impact
More from PCRX